Clinical study of prophylactic hyperthermic intraperitoneal chemotherapy for colorectal cancer
10.12354/j.issn.1000-8179.2024.20241242
- VernacularTitle:预防性腹腔热灌注化疗治疗结直肠癌的临床研究
- Author:
Li FU
1
;
Ren BAOQING
;
Guo CHENYUAN
;
Huang BO
Author Information
1. 山西省人民医院肝胆胰病区(太原市 030000)
- Publication Type:Journal Article
- Keywords:
colorectal cancer(CRC);
hyperthermic intraperitoneal chemotherapy(HIPEC);
lobaplatin;
metastasis
- From:
Chinese Journal of Clinical Oncology
2024;51(24):1267-1272
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the safety and efficacy of prophylactic hyperthermic intraperitoneal chemotherapy(HIPEC)in patients with colorectal cancer(CRC).Methods:The data of 180 patients with CRC at Shanxi Provincial People's Hospital from February 2019 to February 2022 were retrospectively collected and assigned into HIPEC and control groups.Among these patients,53 patients were in the HIPEC group and 127 patients were in the control group.Proensity score matching(PSM)using 1:1 ratio to balance the confounding factors between the two groups and successfully matched to 48 pairs of patients.Results:No significant difference was observed in the occurrence of postoper-ative complications between the HIPEC and control groups(P>0.05).After 2 years of follow-up,a significant decrease was noted in preoper-ative and postoperative carcinoembryonic antigen(CEA)levels in both groups(P<0.05).The overall metastasis rate for early postoperative CRC was 17.65%,which differed significantly between the HIPEC and control groups(9.30%vs.26.19%,P<0.05).Conclusions:HIPEC is safe and feasible for CRC surgery and does not increase the occurrence of postoperative complications.As a perfusion solution,lobaplatin exhib-its minimal toxicity and no apparent side effects.Intraoperative HIPEC can effectively prevent early metastasis of CRC,which is conducive to improved patient prognosis.
